Gene2Cure Foundation and Viralgen Unite to Advance Gene Therapy for Rare Diseases

Gene2Cure Foundation and Viralgen Collaborate to Transform Gene Therapy Landscape



In a groundbreaking partnership, the Gene2Cure Foundation, a non-profit organization dedicated to advancing clinical gene therapy for rare pediatric diseases, has joined forces with Viralgen, a leading contract development and manufacturing organization (CDMO) specializing in adeno-associated virus (AAV) based therapies. This collaboration is set to make significant strides in the treatment of rare and ultra-rare genetic diseases, meeting substantial unmet medical needs.

The Essence of the Collaboration



The partnership focuses on leveraging Viralgen's proprietary Aava™ platform to enhance the development of Gene2Cure’s gene therapy portfolio. Initially, this initiative targets several rare genetic disorders, including PUS3 syndrome, Smith-Lemli-Opitz syndrome (SLO), and GAND—conditions that currently pose considerable challenges due to lack of effective treatment options.

Under the agreement, Gene2Cure will utilize Viralgen’s Aava™ manufacturing platform, which is designed to scale with the development of each therapeutic program. This will cover aspects from producing materials for toxicological studies to preparations for clinical use. The Aava™ platform ensures a seamless transition from preclinical development to clinical trials and eventual commercialization, facilitating a faster pathway for innovative therapies to reach the patients who need them.

Quotes from Key Figures



Professor Leszek Lisowski, co-founder and president of the Gene2Cure Foundation, expressed enthusiasm about the collaboration, stating, “We are excited to partner with Viralgen to bring potentially life-saving gene therapies closer to children with incurable genetic diseases. By helping us develop therapies more rapidly and cost-effectively, this collaboration gives hope to affected children and their families.”

Meanwhile, Jimmy Vanhove, CEO of Viralgen, acknowledged the importance of collaboration in advancing potential gene therapies for rare conditions, adding, “We are thrilled to work with Gene2Cure and support the progression of its programs through crucial preclinical and clinical development milestones by granting access to our Aava™ manufacturing platform.”

About Gene2Cure Foundation



Founded in the United States, the Gene2Cure Foundation is a 501(c)(3) nonprofit organization that promotes potentially effective gene therapies for children suffering from rare genetic disorders. With a global presence, the foundation unites scientific, clinical, and industry expertise to transform promising research into clinical treatments for conditions with limited or no therapeutic options. Supported by philanthropic donations, Gene2Cure focuses on delivering safe and effective therapies quickly and affordably, ensuring that every contribution enhances the lives of affected children and their families.

To learn more, visit gene2cure.com and follow Gene2Cure on LinkedIn, Instagram, Facebook, and YouTube.

About Viralgen



Viralgen is a premier contract development and manufacturing organization dedicated solely to AAV-based gene therapies. Established in 2017 as a subsidiary of AskBio, Inc. within Bayer AG, Viralgen provides end-to-end support from early development to large-scale commercial manufacturing. Utilizing its proprietary Pro10™ suspension cell line and Aava™ manufacturing platform, Viralgen ensures high-yield, scalable production of AAV serotypes.

With state-of-the-art facilities located in San Sebastián, Spain, Viralgen boasts three AEMPS-certified cGMP suites, each with a capacity of 2,000 liters, while offering a range of services such as plasmid production, process optimization, fill-finish, and in-house quality control testing. With over 2,000 produced AAV batches, Viralgen is committed to providing reliable and efficient solutions that allow patients access to transformative gene therapies faster and more consistently.

To find out more, visit viralgen.com and connect with Viralgen on LinkedIn.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.